Literature DB >> 19188397

Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.

Hoang Anh Nguyen1, Olivier Denis, Anne Vergison, Paul M Tulkens, Marc J Struelens, Françoise Van Bambeke.   

Abstract

In a companion paper (H. A. Nguyen et al., Antimicrob. Agents Chemother. 53:1434-1442, 2009), we showed that vancomycin, oxacillin, fusidic acid, clindamycin, linezolid, and daptomycin are poorly active against the intracellular form of a thymidine-dependent small-colony variant (SCV) strain isolated from a cystic fibrosis patient and that the activity of quinupristin-dalfopristin, moxifloxacin, rifampin, and oritavancin remains limited (2- to 3-log CFU reduction) compared to their extracellular activity. Antibiotic combination is a well-known strategy to improve antibacterial activity, which was examined here against an intracellular SCV strain using combinations with either rifampin or oritavancin. Time-kill curve analysis using either concentrations that caused a static effect for each antibiotic individually or concentrations corresponding to the maximum concentration in human serum showed largely divergent effects that were favorable when antibiotics were combined with rifampin at low concentrations only and with oritavancin at both low and high concentrations. The nature of the interaction between rifampin, oritavancin, and moxifloxacin was further examined using the fractional maximal effect method, which allows categorization of the effects of combinations when dose-effect relationships are not linear. Rifampin and oritavancin were synergistic at all concentration ratios investigated. Oritavancin and moxifloxacin were also synergistic but at high oritavancin concentrations only. Rifampin and moxifloxacin were additive. This approach may help in better assessing and improving the activity of antibiotics against intracellular SCV strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188397      PMCID: PMC2663110          DOI: 10.1128/AAC.01146-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Stability of antimycobacterial drugs in susceptibility testing.

Authors:  M E Griffith; H L Bodily
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 2.  Monotherapy versus combination therapy.

Authors:  Shilpa M Patel; Louis D Saravolatz
Journal:  Med Clin North Am       Date:  2006-11       Impact factor: 5.456

3.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors:  R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

5.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing.

Authors:  D M Bamberger; B L Herndon; M Dew; R P Chern; H Mitchell; L E Summers; R F Marcus; S C Kim; P R Suvarna
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions.

Authors:  R C Li; J J Schentag; D E Nix
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae.

Authors:  N Desbiolles; L Piroth; C Lequeu; C Neuwirth; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 9.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

Authors:  Françoise Van Bambeke; Stéphane Carryn; Cristina Seral; Hugues Chanteux; Donatienne Tyteca; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more
  14 in total

Review 1.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors:  Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.

Authors:  Anne Sandberg; Klaus Skovbo Jensen; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

6.  Addition time plays a major role in the inhibitory effect of chitosan on the production of Pseudomonas aeruginosa virulence factors.

Authors:  P Kašparová; S Boková; M Rollová; M Paldrychová; E Vaňková; K Lokočová; J Michailidu; O Maťátková; J Masák
Journal:  Braz J Microbiol       Date:  2022-03-02       Impact factor: 2.214

Review 7.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

Review 8.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

Review 9.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

10.  Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.

Authors:  L G Garcia; S Lemaire; B C Kahl; K Becker; R A Proctor; O Denis; P M Tulkens; F Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.